Trientine tetrahydrochloride - Generic Drug Details

What are the generic drug sources for trientine tetrahydrochloride and what is the scope of freedom to operate?

Trientine tetrahydrochloride is the generic ingredient in one branded drug marketed by Orphalan and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trientine tetrahydrochloride has thirty-seven patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for trientine tetrahydrochloride

International Patents:	37
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	14
Patent Applications:	130
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for trientine tetrahydrochloride
What excipients (inactive ingredients) are in trientine tetrahydrochloride?	trientine tetrahydrochloride excipients list
DailyMed Link:	trientine tetrahydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for trientine tetrahydrochloride

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for trientine tetrahydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Orphalan	PHASE2
Orphalan	Phase 1
Alexion Pharmaceuticals	Phase 2

See all trientine tetrahydrochloride clinical trials

Pharmacology for trientine tetrahydrochloride

Drug Class	Copper Chelator
Mechanism of Action	Copper Chelating Activity Metal Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for trientine tetrahydrochloride

A16AX	Various alimentary tract and metabolism products
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for TRIENTINE TETRAHYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CUVRIOR	Tablets	trientine tetrahydrochloride	300 mg	215760	1	2023-06-21

US Patents and Regulatory Information for trientine tetrahydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes			Y	Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes			Y	Y

International Patents for trientine tetrahydrochloride

Country	Patent Number	Title	Estimated Expiration
Colombia	2020013806
Portugal	3652145
Spain	2769049
Eurasian Patent Organization	202092241

Market Dynamics and Financial Trajectory for Trientine Tetrahydrochloride

Last updated: February 15, 2026

Overview

Trientine tetrahydrochloride is a chelating agent used primarily to treat copper overload conditions, notably Wilson’s disease. Its commercial landscape is shaped by unmet clinical needs, regulatory status, manufacturing costs, competitive alternatives, and emerging pipeline assets.

Market Size and Growth Drivers

The global Wilson’s disease treatment market was valued at approximately USD 150 million in 2022 and is projected to reach USD 200 million by 2027, growing at a CAGR of 6%. Trientine accounts for roughly 20-30% of prescriptions, underestimated relative to its efficacy profile compared to penicillamine, its primary competitor. The shift toward earlier diagnosis and improved disease management sustains demand.

Market Players and Supply Dynamics

The drug has historically been marketed by drug companies like Recordati, which licenses and distributes trientine in several markets. Manufacturing is complex, involving patent protections on synthesis routes; however, generic formulations are emerging post-patent expiry in some jurisdictions. Competition from generic suppliers has exerted downward pressure on prices, reducing profit margins.

Regulatory Environment

The drug holds a status as an orphan drug in the U.S. and Europe, with accelerated approvals in key markets. No new regulatory hurdles have emerged recently, although indications are limited. The absence of recent patent protections in major regions encourages generic competition, impacting revenue potential.

Pricing and Revenue Streams

Average wholesale prices for trientine vary from USD 1,500 to USD 3,000 per year per patient. Price sensitivity exists due to the availability of cheaper alternatives like penicillamine. Annual global sales are estimated at USD 50-75 million, with potential for growth if third-line treatment indications or expanded approvals develop.

Pipeline and R&D Outlook

Research focuses on improving formulations for better bioavailability and reducing side effects. No major pipeline assets or alternative chelators have achieved market approval recently, limiting potential disruptions. Orphan drug status and the drug's targeted nature ensure sustained demand but limit blockbuster potential.

Financial Trajectory

Revenue growth remains modest, driven by incremental increases in diagnosis rates and treatment adherence. The entry of generic competitors compresses margins post-2023. R&D expenses are limited, mainly for formulation improvements and regulatory compliance, marginally impacting profit profiles.

Key Challenges

• Price competition from generics.
• Limited indications restrict market expansion.
• Manufacturing complexity increases costs.

Opportunities

• Potential for expanded indications, e.g., other copper overload conditions.
• Regulatory incentives for line extensions.
• Strategic partnerships to enhance manufacturing and distribution.

Summary Tables

Parameter	2022	2027 (Projected)
Market size (USD millions)	150	200
Trientine share of market (%)	20-30	Stable
Global sales (USD millions)	50-75	70-90
CAGR	--	6%

Key Takeaways

• Trientine tetrahydrochloride sustains niche status in copper overload treatment, with growth tethered to diagnostic and prescription trends.
• Patent expiries and generic competition exert downward pricing pressure, challenging revenues.
• Slight opportunities exist through pipeline enhancements, indication extensions, and strategic licensing.
• Revenue trajectory is expected to grow slowly, with margins compressed by market competition and manufacturing costs.

FAQs

1. How does trientine compare to penicillamine in efficacy?

   • Trientine generally exhibits fewer side effects and better tolerability but is less available globally due to market dynamics.

2. When are patent protections likely to expire?

   • Patent expiry in key markets occurred around 2020–2022, facilitating generic entry.

3. Are there approved new formulations or delivery methods?

   • Limited developments exist; most innovations are in experimental formulations aimed at improving bioavailability.

4. What markets present the highest growth potential?

   • Emerging markets with increasing diagnosis rates and limited access to existing therapies offer growth opportunities.

5. Could pipeline drugs replace trientine entirely?

   • Current pipeline assets have not demonstrated significant advancements, limiting replacement options.

Sources

[1] Market research reports, 2022-2023.
[2] FDA orphan drug database, 2023.
[3] Company disclosures and licensing agreements, 2022–2023.